编号：20230512 | | □分析师会议 □特定对象调研 √业绩说明会 | | --- | --- | | 投资者关系活动 | □媒体采访 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他（2023 年厦门辖区上市公司投资者网上集体接待日） | | 参与单位名称及 | 通过"全景投资者关系互动平台"（http://ir.p5w.net）参与公司 | | 人员姓名 | 年厦门辖区上市公司投资者网上集体接待日活动的投资 2023 | | | 者 | | 时间 | 年 月 日 2023 5 12 14:30-16:15 | | 地点 | "全景投资者关系互动平台"（http://ir.p5w.net） | | 上市公司接待人 | 公司董事长兼总经理江斌先生，董事、副总经理兼财务总监洪 | | 员姓名 | 航先生，独立董事王肖健先生，副总经理兼董事会秘书洪彦女 | | | 士 | | | 公司于 2023 年 5 月 12 日（星期五）14:30-16:15 在"全景 | | | 投资者关系互动平台"（http://ir.p5w.net）参加了 2023 年厦门 辖区上市公司 ...

证券代码：002626 证券简称：金达威 20230504 投资者关系活动记录表 编号：20230504 | | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 投资者关系活动 | √业绩说明会 □媒体采访 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及 | 通过"全景投资者关系互动平台"（http://ir.p5w.net）参与公司 | | | 人员姓名 | 2022 年度业绩说明会的投资者 | | | 时间 | 2023 年 5 月 4 日 15:00-17:00 | | | 地点 | "全景投资者关系互动平台"（http://ir.p5w.net） | | | 上市公司接待人 | 公司董事长兼总经理江斌先生，董事、副总经理兼财务总监洪 | | | 员姓名 | 航先生，独立董事王肖健先生，副总经理兼董事会秘书洪彦女 | | | | 士 | | | | 公司于 年 月 日（星期四）15:00-17:00 2023 5 4 | 在"全景 | | | 投资者关系互动平台"（http://ir.p5w ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥790,491,584.29, representing a 6.61% increase compared to ¥741,447,582.31 in the same period last year[10] - Net profit attributable to shareholders decreased by 27.74% to ¥86,951,244.72 from ¥120,327,135.61 year-on-year[10] - Basic earnings per share fell by 30.00% to ¥0.14 from ¥0.20 in the same period last year[10] - The total operating profit for the period was 107,824,648.14, a decrease of 27.5% compared to 148,675,626.89 in the previous period[22] - The net profit attributable to the parent company was 86,951,244.72, down 27.6% from 120,327,135.61 in the previous period[22] - The total profit for the period was 108,191,544.91, a decrease of 27% compared to 148,408,289.37 in the previous period[22] - The comprehensive income total of ¥59,202,866.61 for the quarter, down from ¥116,127,528.39 in the previous year, representing a decline of about 49.1%[38] Cash Flow - The cash flow from operating activities increased significantly by 117.24% to ¥235,416,458.25 compared to ¥108,367,740.00 in the previous year[10] - The net cash flow from operating activities for the current period is ¥235,416,458.25, an increase from ¥108,367,740.00 in the previous period, representing a growth of approximately 117.5%[40] - Total cash inflow from operating activities is ¥773,671,889.43, compared to ¥705,873,244.92 in the previous period, indicating an increase of about 9.6%[39] - Cash outflow from operating activities decreased to ¥538,255,431.18 from ¥597,505,504.92, reflecting a reduction of approximately 9.9%[40] - The net cash flow from investing activities is ¥111,150,238.00, a significant improvement from -¥75,160,275.89 in the previous period[40] - The net cash flow from financing activities is ¥96,359,432.55, a recovery from -¥251,288,273.67 in the previous period[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,425,734,906.58, a 1.26% increase from ¥5,358,175,766.98 at the end of the previous year[10] - Total liabilities were reported at ¥1,705,710,369.98, slightly up from ¥1,698,374,096.85, indicating a growth of approximately 0.8%[36] - Non-current assets totaled ¥3,212,365,822.55, down from ¥3,251,780,591.30, reflecting a decrease of about 1.2%[35] Research and Development - The company's R&D expenses decreased by 32.41% to ¥14,539,086.42 from ¥21,511,080.15 year-on-year[14] - Research and development expenses for the quarter were ¥14,539,086.42, a decrease from ¥21,511,080.15, indicating a reduction of approximately 32.3%[36] Shareholder Information - The company had a total of 53,964 common shareholders at the end of the reporting period[33] - The largest shareholder, Xiamen Jindawei Investment Co., Ltd., holds 34.71% of the shares, totaling 211,712,732 shares[33] - The second largest shareholder, Zhongmu Industrial Co., Ltd., holds 19.68% of the shares, totaling 120,044,593 shares[33] Tax and Financial Expenses - The income tax expense for the period was 24,556,673.22, down from 27,284,996.86 in the previous period[22] - Financial expenses increased by 45.86% to ¥11,724,795.12, primarily due to increased exchange losses and interest expenses[14] - The company experienced a 74.16% increase in payable taxes, amounting to ¥29,306,182.78 compared to ¥16,827,299.70 in the previous year[14] Investment Income - The company reported a significant increase in investment income, which rose by 565.99% to ¥2,962,426.41 compared to ¥444,817.89 in the previous year[14] Other Comprehensive Income - The other comprehensive income attributable to the parent company was -24,432,005.08, compared to -4,995,764.12 in the previous period, reflecting a worsening in comprehensive income[22] Non-Recurring Gains and Losses - The company reported a total of 4,591,454.23 in non-recurring gains and losses for the period[30]

Financial Performance - The company reported a net profit attributable to shareholders of 120,327,135.61 CNY in Q1 2022, with a decrease to -91,880,290.73 CNY in Q4 2022[25]. - The company's operating revenue for 2022 was ¥3,009,229,135.39, a decrease of 16.78% compared to ¥3,616,159,485.95 in 2021[96]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥256,825,059.58, down 67.44% from ¥788,857,879.79 in the previous year[96]. - The basic earnings per share for 2022 was ¥0.43, a decline of 66.67% compared to ¥1.29 in 2021[96]. - The total assets at the end of 2022 were ¥5,358,175,766.98, representing an 8.37% decrease from ¥5,847,792,136.12 at the end of 2021[96]. - The net assets attributable to shareholders decreased by 8.14% to ¥3,647,404,151.51 from ¥3,970,556,485.97 in 2021[96]. - The company's cash flow from operating activities was ¥695,121,586.16, down 17.96% from ¥847,331,118.18 in the previous year[96]. - The weighted average return on net assets was 6.27%, a decrease of 13.42% from 19.69% in 2021[96]. - The total revenue for 2022 was ¥3,009,229,135.39, a decrease of 16.78% compared to ¥3,616,159,485.95 in 2021[130]. - Revenue from nutritional and health products was ¥2,935,023,179.02, accounting for 97.53% of total revenue, down 16.76% from ¥3,526,123,847.41 in 2021[130]. Market Position and Growth Potential - The company is positioned as a major player in the global dietary supplement industry, benefiting from its comprehensive supply chain and production capabilities[18]. - In 2022, China's per capita spending on health supplements was $33.94, lower than the global average of $38.80 and significantly below the U.S. average of $270.70, indicating substantial growth potential in the market[34]. - The health supplement market in China is projected to reach $63.91 billion by 2027, with a CAGR of 5.64% from 2023 to 2027[34]. - The global NMN market was valued at $255 million in 2021 and is expected to grow to $449 million by 2028, with a CAGR of 8.40%[38]. - As of the end of 2022, the global consumer health supplement market reached $305.9 billion, with the U.S. market at $90.2 billion and China's market at $47.95 billion, representing 29.47% and 15.68% of the global market, respectively[42]. Research and Development - The company has a strong research and development capability, which allows it to continuously launch new products and improve existing production processes[21]. - The company is actively involved in the research and application of NMN, collaborating with Jinan University to expand its usage in aging and regenerative medicine[39]. - The number of R&D personnel increased by 3.08% to 201 in 2022, with a higher proportion of master's degree holders[181]. - Research and development expenses decreased by 13.37% to 71,857,719.17 CNY from 82,946,895.64 CNY in 2021[178]. - The company holds 159 authorized patents, including 155 in China and 4 in the United States, indicating a strong focus on innovation and intellectual property[167]. Sales and Distribution - The company has established a strong presence in overseas markets with brands like Doctor's Best and Zipfizz, achieving high sales on platforms such as Amazon and iHerb[35]. - The company's top five distributors accounted for a total sales revenue of 1,094,878,525.42 RMB, with the largest distributor contributing 12.39% of total sales[127]. - Domestic sales were ¥599,790,200.12, representing 19.93% of total revenue, down 18.68% from ¥737,568,456.28 in 2021[130]. - Online sales of nutritional health products were ¥851,480,814.50, accounting for 28.30% of total revenue, a decrease of 9.27% from ¥938,487,991.22 in 2021[130]. Risks and Challenges - The company faces risks related to goodwill impairment due to acquisitions, which could negatively impact current profits if the acquired companies' operations deteriorate[1]. - The company is exposed to risks related to the political and legal environment of its overseas subsidiaries, which may affect investment decisions[58]. - Environmental protection regulations are becoming stricter, potentially increasing the company's compliance costs and impacting profitability[69]. - The company acknowledges the risk of product price fluctuations due to upstream raw material costs and market supply dynamics, which can affect financial performance[66]. - The company faces increasing competition in the nutritional health food market, which may impact its operational performance if it fails to enhance its competitiveness[55]. Production and Inventory - The production cost of vitamins has increased due to macroeconomic factors and the impact of the Russia-Ukraine conflict, leading to a decline in sales prices to historical lows[41]. - The production volume of nutritional health products was 120,332,288.82 units, with a sales volume of 117,145,229.27 units, reflecting a decrease of 5.98%[147]. - The company reported a significant increase in inventory levels, with total inventory rising to 26,856,958 units, up 13.46% from the previous year[147]. - The inventory of pharmaceutical products increased by 162.05%, primarily due to preparations for shipments of praziquantel at the beginning of 2023[132]. - The inventory of nutritional health products (vitamin raw materials) decreased by 22.36% year-over-year, totaling approximately 547,689 kg[157]. Strategic Initiatives - The company is focusing on expanding its market presence and enhancing internal controls to mitigate risks associated with acquisitions[1]. - The company aims to enhance its brand recognition in the domestic market while leveraging its strong global brands like Doctor's Best and Zipfizz[153]. - The company has established two new subsidiaries in 2022, enhancing its market presence and operational capacity[163]. - The company has made strategic acquisitions, including a 96.11% stake in Doctor's Best and 100% ownership of Zipfizz, enhancing its market presence in the U.S.[198]. Cash Flow and Financial Management - The company reported a net cash flow from investment activities of -241,149,927.74 RMB, a decrease of 22.12% compared to the previous period[129]. - The net cash flow from financing activities was -553,322,479.48 RMB, reflecting a decrease of 4.95% year-on-year[129]. - The company's cash and cash equivalents decreased by 86,423,560.04 RMB, a significant decline of 397.58% due to combined cash flow impacts from operating, investing, and financing activities[129]. - The company reported a significant increase of 803.15% in cash inflow from investment activities, totaling ¥516,630,465.68 compared to ¥57,203,486.56 in the previous year[192].

关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）定于 2023 年 5 月 4 日（星 期四）15:00-17:00 在全景网举办 2022 年度网上业绩说明会，本次年度业绩说明 会将采用网络远程的方式举行，投资者可登陆全景网"投资者关系互动平台" （https://ir.p5w.net）参与本次年度 业绩 说明会或者直 接进 入公司路演厅 （https://ir.p5w.net/c/002626.shtml）参与本次年度业绩说明会。 证券代码：002626 证券简称：金达威 公告编号：2023-025 厦门金达威集团股份有限公司 特此公告。 厦门金达威集团股份有限公司 董 事 会 二〇二三年四月十九日 出席本次说明会的人员有：公司董事长兼总经理江斌先生，董事、副总经理 兼财务总监洪航先生，独立董事王肖健先生，副总经理兼董事会秘书洪彦女士（具 体以当天实际参会人员为准）。 为充分尊重投资者、提升公司与投资者之间的交流效率及针对性，现就公司 2022 年度网上业绩说明会提 ...